- Immuneering to Present at the Jefferies Global Healthcare Conference
- Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
- Immuneering Recognizes Melanoma Awareness Month
- IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
- Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
- Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
- Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
- Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
- Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.10 |
---|---|
High | 1.19 |
Low | 1.09 |
Bid | 1.10 |
Offer | 1.16 |
Previous close | 1.09 |
Average volume | 459.65k |
---|---|
Shares outstanding | 29.65m |
Free float | 21.01m |
P/E (TTM) | -- |
Market cap | 32.32m USD |
EPS (TTM) | -1.86 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼